Loading
Trials tell us a drug works but not where it fits among the others. Commit to answering 'which order' from hospital data within a year of each approval.
The question clinicians face after approval is sequence: first or second line, before or after the previous standard. Trials rarely address it. The proposal is a funded programme that, for every new oncology approval, runs a pre-registered target trial emulation of sequencing strategies in federated data within 12 months, published in a standard format and fed into guidelines as explicitly graded real-world evidence.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries.
Shares ADC sequencing, Too many combinations to test, Real-world evidence, Weak real-world evidence and registries.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries.